BAVARIAN NORDIC A/S/ DK0015998017 /
31/05/2024 16:51:47 | Chg. +6.00 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
183.45DKK | +3.38% | 6,737 Turnover: 1.22 mill. |
-Bid Size: - | -Ask Size: - | 184.85 | 176.20 |
GlobeNewswire
16:33
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Sm...
GlobeNewswire
07/05
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
29/04
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chiku...
GlobeNewswire
20/03
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
23/02
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...
GlobeNewswire
09/11/2023
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
21/09/2023
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
21/03/2022
Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Com...
GlobeNewswire
28/02/2022
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead...
GlobeNewswire
14/02/2022
Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Pre...
GlobeNewswire
03/02/2022
Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
GlobeNewswire
06/12/2021
Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening it...
GlobeNewswire
05/12/2021
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate